FDA Approves Benralizumab for Hypereosinophilic Syndrome
Benralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Tag: benralizumab
All
Latest
FDA Approves Benralizumab for Hypereosinophilic Syndrome
Benralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read More
Fasenra Delayed Time to First Flare or Worsening of Hypereosinophilic Syndrome
A Phase III NATRON trial found Fasenra (benralizumab) had benefits for patients with hypereosinophilic syndrome (HES).
Read More
Benralizumab Outperforms Steroids in Treating Asthma and COPD Flare-Ups
Benralizumab injection improved respiratory symptoms within 28 days and reduced treatment failures by fourfold after 90 days compared to standard steroid therapy.
Read More
Benralizumab Effective for EGPA Patients
More than half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved remission when treated with benralizumab (Fasenra).
Read More
Benralizumab Reduces Need for Inhaled Steroids for Severe Asthma
Findings from a multinational study demonstrated that 92% of patients using benralizumab could safely reduce inhaled steroid dose, and more than 60% could stop all use.
Read More
Severe Asthma Management
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read MoreCytokine Levels Could Predict Asthma Patients’ Response to Benralizumab
Levels of inflammatory cytokines in patients with severe asthma may predict responses to the monoclonal antibody benralizumab, a study in the Journal of Asthma suggests.
Read More
Long-term Data Shows Safety, Effectiveness of Fasenra for Severe Eosinophilic Asthma
A five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
Read MoreFasenra Approved for Home Use
Benralizumab (Fasenra) has been approved for self-administration by patients and caregivers by the US FDA, according to AstraZeneca.
Read More![Long-Term Benralizumab Appears Safe, Effective for Severe Asthma [Corrected]](https://respiratory-therapy.com/wp-content/uploads/2016/07/dreamstime_s_43463378-627x376.jpg)
Long-Term Benralizumab Appears Safe, Effective for Severe Asthma [Corrected]
Patients with severe eosinophilic asthma treated long-term with benralizumab (Fasenra) continued to experience fewer exacerbations and improved pulmonary function and quality of life.
Read MoreClinical Characteristics in Severe Asthma Could Help Treatment
Certain key clinical characteristics in patients with severe asthma may help clinicians ID those who may benefit from additional targeted drug therapy, such as benralizumab.
Read More